Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study, Cladribine Tablets significantly improved clinical and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing-remitting multiple sclerosis. Describe two clinically relevant definitions for patien...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Multiple sclerosis Ročník 25; číslo 6; s. 819
Hlavní autori:	Giovannoni, Gavin, Soelberg Sorensen, Per, Cook, Stuart, Rammohan, Kottil W, Rieckmann, Peter, Comi, Giancarlo, Dangond, Fernando, Hicking, Christine, Vermersch, Patrick
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.05.2019
Predmet:	Adult Cladribine - administration & dosage Cladribine - adverse effects Cladribine - pharmacology Disease Progression Female Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - pharmacology Magnetic Resonance Imaging Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - physiopathology Outcome Assessment, Health Care Severity of Illness Index Cladribine Tablets risk:benefit high disease activity safety efficacy
ISSN:	1477-0970, 1477-0970
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!